UroGen Pharma Ltd. (URGN)
A
Pipeline Grade
Financial Position (from SEC Filings)
$110.0M
Cash & Equivalents
$45.3M
Quarterly Burn Rate
7 mo
Est. Cash Runway
$1,377M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
MITOMYCIN
JELMYTO |
APPROVED | Bladder Cancer, Carcinoma, Carcinoma in Situ of Bladder, Carcinoma of Urinary Bladder, Invasive, Carcinoma of Urinary Bladder, Superficial, Carcinoma, Transitional Cell, Interstitial Cystitis, Neoplasms, NMIBC, Non-muscle Invasive Bladder Cancer, Overactive Bladder, Transitional Cell Cancer of the Renal Pelvis and Ureter, Transitional Cell Carcinoma, Transitional Cell Carcinoma of Renal Pelvis, Upper Urinary Tract Urothelial Carcinoma, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urologic Diseases, Urologic Neoplasms, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Carcinoma Ureteral Location |
Upcoming Catalysts
No upcoming catalysts detected for this company.